Clinical characteristics of adrenal insufficiency induced by pembrolizumab in non-small-cell lung cancer.

Kana KurokawaYoichiro MitsuishiNaoko ShimadaNaoaki ItoMisa OgiwaraKeita MiuraTetsuhiko AsaoRyo Ko Takehito ShukuyaRina ShibayamaHiromasa GotoKazuhisa Takahashi

Published in: Thoracic cancer (2022)

The incidence of AI among patients treated with pembrolizumab is more frequent than previously reported. In addition, secondary AI, especially isolated ACTH deficiency, is a major form of AI induced by pembrolizumab.

Keyphrases

artificial intelligence
advanced non small cell lung cancer
machine learning
risk factors
epidermal growth factor receptor
replacement therapy